Literature DB >> 18515902

Association of cannabis use with prodromal symptoms of psychosis in adolescence.

Jouko Miettunen1, Sari Törmänen, Graham K Murray, Peter B Jones, Pirjo Mäki, Hanna Ebeling, Irma Moilanen, Anja Taanila, Markus Heinimaa, Matti Joukamaa, Juha Veijola.   

Abstract

Recent interest has focused on the association between cannabis use and risk of psychosis. In the largest unselected, population-based study on this topic to date, we examined cannabis use and prodromal symptoms of psychosis at age 15-16 years among 6330 adolescents. Those who had tried cannabis (n=352; 5.6% of the total sample) were more likely to present three or more prodromal symptoms even after controlling for confounders including previous behavioural symptoms (OR=2.23; 95% CI 1.70-2.94). A dose-response effect was seen. We conclude that cannabis use is associated with prodromal symptoms of psychosis in adolescence.

Entities:  

Mesh:

Year:  2008        PMID: 18515902     DOI: 10.1192/bjp.bp.107.045740

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  17 in total

1.  Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis.

Authors:  Michael T Compton; Beth Broussard; Claire E Ramsay; Tarianna Stewart
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

Review 2.  Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models.

Authors:  Daniel T Malone; Matthew N Hill; Tiziana Rubino
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Adolescent cannabis exposure interacts with mutant DISC1 to produce impaired adult emotional memory.

Authors:  Michael D Ballinger; Atsushi Saito; Bagrat Abazyan; Yu Taniguchi; Ching-Hsun Huang; Koki Ito; Xiaolei Zhu; Hadar Segal; Hanna Jaaro-Peled; Akira Sawa; Ken Mackie; Mikhail V Pletnikov; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2015-06-18       Impact factor: 5.996

Review 4.  Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Authors:  Atsushi Saito; Michael D L Ballinger; Mikhail V Pletnikov; Dean F Wong; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

5.  Associations between psychotic-like symptoms and inattention/hyperactivity symptoms.

Authors:  Tuula Marketta Hurtig; Anja Taanila; Juha Veijola; Hanna Ebeling; Pirjo Mäki; Jouko Miettunen; Marika Kaakinen; Matti Joukamaa; Sebastian Therman; Markus Heinimaa; Marjo-Riitta Järvelin; Irma Moilanen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-11-12       Impact factor: 4.328

6.  High-potency cannabis and the risk of psychosis.

Authors:  Marta Di Forti; Craig Morgan; Paola Dazzan; Carmine Pariante; Valeria Mondelli; Tiago Reis Marques; Rowena Handley; Sonija Luzi; Manuela Russo; Alessandra Paparelli; Alexander Butt; Simona A Stilo; Ben Wiffen; John Powell; Robin M Murray
Journal:  Br J Psychiatry       Date:  2009-12       Impact factor: 9.319

Review 7.  Role of cannabis and endocannabinoids in the genesis of schizophrenia.

Authors:  Emilio Fernandez-Espejo; Maria-Paz Viveros; Luis Núñez; Bart A Ellenbroek; Fernando Rodriguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  2009-07-24       Impact factor: 4.530

8.  Animal Models of Psychosis: Current State and Future Directions.

Authors:  Alexandra D Forrest; Carlos A Coto; Steven J Siegel
Journal:  Curr Behav Neurosci Rep       Date:  2014-06-01

Review 9.  Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia.

Authors:  Marc Fakhoury
Journal:  Mol Neurobiol       Date:  2016-01-15       Impact factor: 5.590

Review 10.  Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.

Authors:  Arianna Marconi; Marta Di Forti; Cathryn M Lewis; Robin M Murray; Evangelos Vassos
Journal:  Schizophr Bull       Date:  2016-02-15       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.